• The MRF launches a program to include patients and caregivers with researchers into grant review panels.
  • The MRF launches its Mucosal Melanoma Steering Committee to increase the focus on this rare melanoma subtype.
  • The MRF advocates for increased Department of Defense melanoma research funding, which is doubled to $20M.
  • FDA approves pembrolizumab as 2nd PD-L1 checkpoint inhibitor for the adjuvant treatment of resected melanoma.